[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU59602A - Aryl fused azapolycyclic compounds - Google Patents

Aryl fused azapolycyclic compounds

Info

Publication number
YU59602A
YU59602A YU59602A YUP59602A YU59602A YU 59602 A YU59602 A YU 59602A YU 59602 A YU59602 A YU 59602A YU P59602 A YUP59602 A YU P59602A YU 59602 A YU59602 A YU 59602A
Authority
YU
Yugoslavia
Prior art keywords
compounds
aryl fused
fused azapolycyclic
azapolycyclic compounds
aryl
Prior art date
Application number
YU59602A
Other languages
Serbo-Croatian (sh)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU59602A publication Critical patent/YU59602A/en
Publication of RS51123B publication Critical patent/RS51123B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention is directed to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.
YUP-596/02A 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds RS51123B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
YU59602A true YU59602A (en) 2005-06-10
RS51123B RS51123B (en) 2010-10-31

Family

ID=24045406

Country Status (40)

Country Link
US (3) US6605610B1 (en)
EP (2) EP1619192B1 (en)
JP (1) JP2003524002A (en)
KR (1) KR100537976B1 (en)
CN (1) CN1263745C (en)
AP (1) AP1860A (en)
AT (2) ATE328872T1 (en)
AU (2) AU784081B2 (en)
BG (1) BG65891B1 (en)
BR (1) BR0108610A (en)
CA (1) CA2401229C (en)
CR (1) CR6726A (en)
CU (1) CU23148A3 (en)
CY (1) CY1105301T1 (en)
CZ (1) CZ303203B6 (en)
DE (2) DE60120366T2 (en)
DK (2) DK1619192T3 (en)
DZ (1) DZ3328A1 (en)
EA (1) EA005316B1 (en)
EE (1) EE200200475A (en)
ES (2) ES2263640T3 (en)
GE (1) GEP20053454B (en)
HK (1) HK1050894A1 (en)
HR (1) HRP20020700A2 (en)
HU (1) HU229482B1 (en)
IL (2) IL150639A0 (en)
IS (1) IS2293B (en)
MA (1) MA26875A1 (en)
MX (1) MXPA02008311A (en)
NO (1) NO323608B1 (en)
NZ (1) NZ519973A (en)
OA (1) OA12181A (en)
PL (1) PL365163A1 (en)
PT (1) PT1259489E (en)
RS (1) RS51123B (en)
SI (1) SI1259489T1 (en)
SK (1) SK12042002A3 (en)
UA (1) UA74813C2 (en)
WO (1) WO2001062736A1 (en)
ZA (1) ZA200206768B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00459B (en) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aryl fused azapolycyclic compounds
BR0208992A (en) * 2001-04-20 2004-04-27 Pfizer Prod Inc Process for the preparation of 1,3-substituted indenes and aryl fused azapolytic compounds
WO2003037329A1 (en) * 2001-10-31 2003-05-08 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
CN1864663A (en) * 2001-11-30 2006-11-22 辉瑞产品公司 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2 (11),3,5,7,9-pentaene
EP1451202B1 (en) * 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2004009116A2 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
MXPA05007565A (en) * 2003-01-15 2005-09-21 Pfizer Prod Inc Process for the preparation of aryl fused polycyclic lactams.
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
PL378491A1 (en) * 2003-06-04 2006-05-02 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
MXPA06000892A (en) * 2003-07-21 2006-03-30 Pfizer Prod Inc Aryl fused azapolycyclic compounds.
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1677767B1 (en) 2003-10-14 2011-07-20 XenoPort, Inc. Crystalline form of gamma-aminobutyric acid analog
CA2549638A1 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
CN101128462A (en) * 2005-02-24 2008-02-20 辉瑞产品有限公司 Preparation of high purity substituted quinoxaline
RU2403016C2 (en) * 2006-04-24 2010-11-10 Пфайзер Продактс Инк. Asymmetric membranes for drug delivery devices
MX2009005043A (en) * 2006-11-09 2009-05-25 Pfizer Prod Inc Polymorphs of nicotinic intermediates.
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (en) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp OXINDOL DERIVATIVES REPLACED, MEDICINES THAT UNDERSTAND AND USE THEMSELVES
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
US8703774B2 (en) * 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2398676T3 (en) * 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Amidomethyl substituted oxindole derivatives and their use for the production of a drug for the treatment of vasopressin-dependent diseases
US8546401B2 (en) * 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
AU2008333123C1 (en) * 2007-12-07 2014-06-19 AbbVie Deutschland GmbH & Co. KG 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (en) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ Treatment of disease-induced ataxia and ataxia imbalance
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010023561A1 (en) * 2008-09-01 2010-03-04 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
RU2011137419A (en) 2009-02-11 2013-03-20 Суновион Фармасьютикалз Инк. REVERSE AGONISTS AND HISTAMINE H3 ANTAGONISTS AND WAYS OF THEIR APPLICATION
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
RU2012102052A (en) * 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. SOLID FORMS OF VARENIKLIN SALTS AND METHODS FOR THEIR PRODUCTION
KR20180101268A (en) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 Oral dosage formulation comprising inclusion complex of the Varenicline or a pharmaceutically acceptable salt thereof
CA3161867A1 (en) * 2020-01-03 2021-07-08 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating cns disorders
CN115322105A (en) * 2021-05-11 2022-11-11 江苏润安制药有限公司 Method for synthesizing Iguratimod key intermediate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
ME00459B (en) * 1997-12-31 2011-10-10 Pfizer Prod Inc Aryl fused azapolycyclic compounds
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
YU64400A (en) 1998-04-29 2003-01-31 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2000044755A1 (en) * 1999-01-29 2000-08-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (en) * 1999-02-02 2002-08-02 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE AND THEIR APPLICATION IN SMOKING WITHDRAWAL
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CA2441822A1 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
MXPA06000892A (en) * 2003-07-21 2006-03-30 Pfizer Prod Inc Aryl fused azapolycyclic compounds.
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
HUP0204580A2 (en) 2003-04-28
KR100537976B1 (en) 2005-12-21
CZ303203B6 (en) 2012-05-23
NO20024042L (en) 2002-10-17
NZ519973A (en) 2004-04-30
US20030130260A1 (en) 2003-07-10
IL150639A0 (en) 2003-02-12
CR6726A (en) 2003-10-28
ATE453643T1 (en) 2010-01-15
PT1259489E (en) 2006-08-31
ES2336800T3 (en) 2010-04-16
BG65891B1 (en) 2010-04-30
DE60120366T2 (en) 2007-07-05
AP1860A (en) 2008-07-02
EP1619192A3 (en) 2006-03-22
HUP0204580A3 (en) 2005-04-28
DK1259489T3 (en) 2006-10-09
MA26875A1 (en) 2004-12-20
GEP20053454B (en) 2005-02-25
UA74813C2 (en) 2006-02-15
ES2263640T3 (en) 2006-12-16
CN1406227A (en) 2003-03-26
DK1619192T3 (en) 2010-03-29
EP1619192B1 (en) 2009-12-30
MXPA02008311A (en) 2002-12-09
EP1259489B1 (en) 2006-06-07
IS2293B (en) 2007-10-15
BR0108610A (en) 2002-11-19
CN1263745C (en) 2006-07-12
RS51123B (en) 2010-10-31
US20030130261A1 (en) 2003-07-10
DE60120366D1 (en) 2006-07-20
NO323608B1 (en) 2007-06-18
CA2401229C (en) 2007-10-02
DZ3328A1 (en) 2001-08-30
EA005316B1 (en) 2004-12-30
SI1259489T1 (en) 2006-10-31
AU2005234671A1 (en) 2005-12-15
JP2003524002A (en) 2003-08-12
OA12181A (en) 2006-05-09
SK12042002A3 (en) 2004-02-03
EE200200475A (en) 2003-12-15
CU23148A3 (en) 2006-06-29
CY1105301T1 (en) 2010-03-03
AU2874801A (en) 2001-09-03
CA2401229A1 (en) 2001-08-30
EA200200716A1 (en) 2003-02-27
WO2001062736A1 (en) 2001-08-30
NO20024042D0 (en) 2002-08-23
US6605610B1 (en) 2003-08-12
AP2002002604A0 (en) 2002-09-30
PL365163A1 (en) 2004-12-27
KR20030005209A (en) 2003-01-17
BG106908A (en) 2003-04-30
AU2005234671B2 (en) 2008-04-17
AU784081B2 (en) 2006-02-02
DE60140965D1 (en) 2010-02-11
HU229482B1 (en) 2014-01-28
IL150639A (en) 2011-10-31
ATE328872T1 (en) 2006-06-15
CZ20022778A3 (en) 2003-09-17
EP1259489A1 (en) 2002-11-27
US7205300B2 (en) 2007-04-17
EP1619192A2 (en) 2006-01-25
ZA200206768B (en) 2003-09-23
US7144882B2 (en) 2006-12-05
HK1050894A1 (en) 2003-07-11
HRP20020700A2 (en) 2004-12-31
IS6459A (en) 2002-07-05

Similar Documents

Publication Publication Date Title
YU59602A (en) Aryl fused azapolycyclic compounds
MY118163A (en) Aryl fused azapolycyclic compounds
YU95102A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
SI1678166T1 (en) Protein kinase inhibitors
EA200600811A1 (en) NEW TETRAHYDROSPIRO {PIPERIDIN-2,7'-PYRROLO [3,2-b] PYRIDINE} DERIVATIVES AND NEW INDOLA DERIVATIVES, APPLICATION FOR THE TREATMENT OF DISORDERS RELATED TO 5-HT-RECEPTOR
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
MY138352A (en) Benzothiazole derivatives
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
AP9701146A0 (en) Fused bicyclic pyrimidine derivatives.
MA27769A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, their preparation and their therapeutic application
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
YU64400A (en) Aryl fused azapolycyclic compounds
TWI264437B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
MXPA01007940A (en) Azabicycloalkane derivatives and therapeutic uses thereof.
MXPA06000892A (en) Aryl fused azapolycyclic compounds.
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.
HUP0302255A2 (en) Sulfonamide derivatives, pharmaceutical compositions containing them and their use
TW200514779A (en) Imidazole derivatives III
EP1057829A4 (en) Novel compounds and pharmaceutical compositions containing the same
MXPA04003688A (en) Aryl fused azapolycyclic compounds.
ECSP992933A (en) ARYL-CONDENSED AZAPOLYCLIC COMPOUNDS